Amgen (NASDAQ: AMGN) Faces Downgrade Amidst Novartis Clinical Trial Setback: A Biopharmaceutical Stock Analysis
| Show full article |
|
This functionality is available for registred users only
|
-
Full nameAmgen, Inc.
-
Registration countryUSA
-
IndustryPharmaceutical Preparation and Biotechnology
-
М/S&P/F
*** /*** /***









